Skip to main content
. 2023;26(3):639–651. doi: 10.2174/1386207325666220629162823

Table 1.

Clinical features of invasive breast cancer patients in TCGA.

Characteristic Low Expression of TIGIT High Expression of TIGIT p
n 532 533 -
T stage, n (%) - - 0.004
T1 143 (13.5%) 132 (12.4%) -
T2 283 (26.6%) 332 (31.3%) -
T3 78 (7.3%) 59 (5.6%) -
T4 25 (2.4%) 10 (0.9%) -
N stage, n (%) - - 0.467
N0 259 (24.8%) 248 (23.7%) -
N1 171 (16.3%) 178 (17%) -
N2 50 (4.8%) 66 (6.3%) -
N3 38 (3.6%) 36 (3.4%) -
M stage, n (%) - - 0.236
M0 436 (48%) 453 (49.8%) -
M1 13 (1.4%) 7 (0.8%) -
Pathologic stage, n (%) - - 0.059
Stage I 103 (9.9%) 77 (7.4%) -
Stage II 287 (27.5%) 319 (30.6%) -
Stage III 118 (11.3%) 120 (11.5%) -
Stage IV 12 (1.2%) 6 (0.6%) -
Age, n (%) - - 0.013
<=60 273 (25.6%) 315 (29.6%) -
>60 259 (24.3%) 218 (20.5%) -
Histological type, n (%) - - 0.917
Infiltrating Ductal Carcinoma 369 (38.5%) 388 (40.5%) -
Infiltrating Lobular Carcinoma 97 (10.1%) 105 (10.9%) -
PR status, n (%) - - < 0.001
Negative 138 (13.6%) 200 (19.7%) -
Indeterminate 2 (0.2%) 2 (0.2%) -
Positive 362 (35.6%) 312 (30.7%) -
ER status, n (%) - - < 0.001
Negative 79 (7.8%) 158 (15.5%) -
Indeterminate 1 (0.1%) 1 (0.1%) -
Positive 423 (41.6%) 355 (34.9%) -
HER2 status, n (%) - - 0.388
Negative 264 (36.8%) 284 (39.6%) -
Indeterminate 6 (0.8%) 6 (0.8%) -
Positive 66 (9.2%) 91 (12.7%) -
PAM50, n (%) - - < 0.001
Normal 16 (1.5%) 24 (2.3%) -
LumA 323 (30.3%) 228 (21.4%) -
LumB 103 (9.7%) 99 (9.3%) -
Her2 25 (2.3%) 57 (5.4%) -
Basal 65 (6.1%) 125 (11.7%)
Menopause status, n (%) - - 0.209
Pre 104 (10.9%) 120 (12.6%) -
Peri 24 (2.5%) 15 (1.6%) -
Post 345 (36.1%) 348 (36.4%) -
Radiation_therapy, n (%) - - 0.158
No 227 (23.4%) 205 (21.1%) -
Yes 258 (26.5%) 282 (29%) -
OS event, n (%) - - 0.049
Alive 447 (42%) 471 (44.2%) -
Dead 85 (8%) 62 (5.8%) -
DSS event, n (%) - - 0.233
Alive 475 (45.4%) 490 (46.8%) -
Dead 46 (4.4%) 35 (3.3%) -
PFI event, n (%) - - 0.103
Alive 451 (42.3%) 471 (44.2%) -
Dead 81 (7.6%) 62 (5.8%) -